HPV vaccination coverage by dose number (Australia) for males by age group in mid 2017

Graph 1. HPV vaccination coverage by dose number for males by age group in mid 2017.

Table 1. HPV vaccination coverage by dose number for males by age group in mid 2017.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Age (in years at mid 2017) | 12-13 | 14-15 | 16-17 | 18-19 | 20-26 |
| Population(in years at mid 2017) | 296,712 | 290,074 | 299,480 | 315,305 | 1,248,755 |
| Total no. of doses notified | \* | 708,613 | 669,212 | 444,608 | 13,660 |
| Coverage Rate (as at 30 June 2018) | **DOSE 1** | \* | 86% | 79% | 51% | 0% |
| **DOSE 2** | \* | 82% | 76% | 48% | 0% |
| **DOSE 3** | \* | 76% | 69% | 42% | 0% |

 Vaccine data not yet complete for this age group

* In some State those aged 12-13 in 2017 are not eligible for vaccination until 2018. Notification of 2018 to the Register is in progress.

# Notes:

* Data extracted from the National HPV Vaccination Program Register (HPV Register) as at 4 July 2018 and includes females vaccinated between April 2007 and June 2018.
* Includes doses that comply with the recommended vaccine dosage and administration as per the Australian Immunisation Handbook (up to 3 doses administered at prescribed intervals).
* Estimated Resident Population 2017 (as at 30/6/2017) is from the Australian Bureau of Statistics - CAT 3101.0 Australian Demographic Statistics, Tables 51 to 58: Estimated Resident Population by Single Year of Age by State and Territory, PRELIMINARY based on 2016 census data published June 2018.
* Age is age as at date of ERP estimate (30th June 2017).
* Coverage is calculated as doses administered and reported to the HPV Register/Estimated Resident Population expressed as a percentage.
* Excludes consumers who do not wish their details to be recorded on the HPV Register.
* Dose number is calculated according to the number of doses held by the register for each person. Incoming records are matched to existing records for that person and date of administration is used to determine the dose number.
* The National HPV Vaccination Program initially provided quadrivalent HPV vaccine for all females aged 12-26 years as at mid 2007 (school program commenced April 2007 and GP/community program in July 2007) until end December 2009. From 2009 the Program offered HPV vaccination routinely to females in the first year of high school (usually at 12-13 years). From 2013, males were also offered HPV vaccination routinely in the first year of high school (age 12-13 years), with a catch-up program available for males aged 14-15 years in 2013 and 2014.
* HPV Vaccination doses administered through general practice and in other community settings may be incompletely notified to the HPV Register. The extent of under notification differs by jurisdiction, with the Northern Territory and Queensland expected to have the most complete notification, due to notification of doses via State based immunisation registers.